Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Air pollution may be quietly working against childhood leukemia treatment. A new study found that children with high-risk B-cell acute lymphoblastic leukemia (B-ALL) exposed to higher residential fine particulate matter (PM2.5) during induction therapy were more likely to have detectable residual cancer cells at the end of treatment — suggesting that where a child lives could meaningfully affect how well their leukemia responds to therapy.
Air pollution may be quietly working against childhood leukemia treatment. A study published in JNCI Cancer Spectrum found that pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) who lived in areas with higher fine particulate matter (PM2.5) concentrations during induction therapy were significantly more likely to test positive for minimal residual disease (MRD) — meaning detectable cancer cells — at the end of induction. MRD status is a key predictor of relapse risk and long-term outcomes.
Researchers at Baylor College of Medicine analyzed data from 2,125 pediatric ALL patients, linking daily PM2.5 estimates to patients' home addresses and treatment centers. The association was especially pronounced among those classified as National Cancer Institute high-risk B-ALL.
By the Numbers:
Why it matters: This study reinforces the growing evidence that environmental exposures don't just cause cancer — they can also interfere with how well children respond to treatment. Reducing PM2.5 exposure during therapy could become an important, actionable intervention to improve outcomes in pediatric leukemia.
